The Anxiolytic-Like Effects of the Novel, Orally Active Nociceptin Opioid Receptor Agonist 8-[bis(2-Methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510)
Geoffrey B. Varty(Institute of Neurobiology), Galen Carey, Vicki L. Coffin, Mary Cohen-Williams, Cynthia A. Morgan, Deen Tulshian, Robert A. Hodgson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongtao Zhang(Chinese Academy of Sciences), Sherry Lu, Ginny D. Ho, Ahmad Fawzi, April Smith‐Torhan, Michael P. Graziano(University of Hartford), Julius J. Matasi
Cited by 83
Related Papers
Protein misfolding in neurodegenerative diseases: implications and strategies
|Translational Neurodegeneration|2017|671
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435